期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

用于帕金森病治疗的单胺氧化酶B抑制剂的临床评述 被引量：7

Survey on monoamine oxidases B inhibitors as therapy drug of Parkinson′s disease in clinical practice
原文传递
导出
摘要 单胺氧化酶B抑制剂可用于帕金森病早期的单药治疗及出现症状波动后的辅助治疗。本文对目前已经上市或已进入临床试验研究的不可逆性及可逆性、选择性单胺氧化酶B抑制剂进行了分类阐述,并对其药理学性质和临床研究结果进行评述。 Monoamine oxidase B inhibitors are available both in monotherapy of early Parkinson＇s disease and in add-on therapy of advanced Parkinson＇s disease. This survey focuses on the monoamine oxidase B inhibitors in clinical use or on clinical trials. Irreversible （seleginlie, rasagiline and mofegiline） and reversible （safinamide and lazabemide）, selective monoamine oxidase B inhibitors are described and their pharmacological properties and clinical trial results are reviewed.
作者 沈鸿雁 徐赫男 胡春
机构地区 沈阳药科大学制药工程学院
出处 《中国药物化学杂志》 CAS CSCD 2011年第6期483-488,共6页 Chinese Journal of Medicinal Chemistry
基金 国家自然科学基金项目(21072130)
关键词 单胺氧化酶抑制剂 帕金森病 临床试验 monoamine oxidase B inhibitor Parkinson＇s disease clinicaltrial
分类号 R742.5 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献35

  • 1吴铁,冯冰虹.药理学[M].北京:科学出版社,2010:435-6.
  • 2BRUNTON L L,PARKER K L.药理学和治疗学手册[M].北京:科学出版社,2009:324-332.
  • 3张瑜,胡林森,王秋艳.单胺氧化酶B抑制剂对帕金森病的治疗作用[J].临床荟萃,2006,21(13):979-981. 被引量：2
  • 4李淑华.单胺氧化酶B抑制剂在帕金森病治疗中的作用[J].中国神经免疫学和神经病学杂志,2010,17(3):221-223. 被引量：3
  • 5张克忠,蒋雨平.单胺氧化酶B抑制剂在治疗帕金森病中的研究[J].中国临床神经科学,2008,16(2):179-182. 被引量：12
  • 6NAOI M, MARUYAMA W. Monoamine oxidase in- hibitors as neuroprotective agents in age-dependent neurodegenerafive disorders [ J ]. Curr Pharm Des, 2010,16 (25) :2799 - 2817.
  • 7EDMONDSON D E, BINDA C, MATTEVI A. Structural insights into the mechanism of amine oxi- dation by monoamine oxidases A and B [ J ]. Arch Biochem Biophys ,2007,464 (2) :269 - 276.
  • 8ROBOTTOM B J. Efficacy, safety, and patient pre- ference of monoamine oxidase B inhibitors in the treatment of Parkinson' s disease [ J ]. Patient Prefer Adherence,2011,5:57 - 64.
  • 9HENCHCLIFFE C, SCHUMACHER H C, BURGUT F T. Recent advances in Parkinson's disease thera- py: use of monoamine oxidase inhibitors [ J ]. Expert Rev Neurother, 2005,5 ( 6 ) : 811 - 821.
  • 10BLANDINI F. Neuroprotective compounds and inno- vative therapeutic strategies for Parkinson's disease: experimental and clinical studies [J ]. Open Access J Clin Trial ,2009,1 : 1 - 15.

二级参考文献39

  • 1Moussa BH,Youdim MBH,Peter F.A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease[J].Neurology,2004,63(7 Suppl 2):S32-35.
  • 2Youdim MBH,Gross A,Finberg JPM.Rasagiline[N-propargyl-1R (+)-aminoindant],a selective and potent inhibitor of mitochondrial monoamine oxidase B[J].Br J Pharmacol,2001,132 (2):500-506.
  • 3Birkmayer W,Riederer P,Youdim MB,et al.The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B,deprenil[J].J Neural Transm,1975,36(34):303-326.
  • 4Yamada M,Yasuhara H.Clinical pharmacology of MAO inhibitors:safety and future[J].Neurotoxicology,2004,25(12):215-221.
  • 5Kondo T,Takubo H,Yokochi F,et al.Long-term treatment of Parkinson's disease patients with selegiline hydrochloride (FPF 1100):outcome of 5-year treatment[J].No To Shinkei,2002,54(12):1041-1048.
  • 6Cohen G,Spina MB.Deprenyl suppresses the oxidant stress associated with increased dopamine turnover[J].Ann Neurol,1989,26(5):689 -690.
  • 7Kitani K,Minami C,Isobe K,et al.Why (-)deprenyl prolongs survivals of experimental animals:increase of anti-oxidant enzymes in brain and other body tissues as well as mobilization of various humoral factors may lead to systemic anti-aging effects[J].Mech Ageing Dev,2002,123(8):1087-1100.
  • 8Lamensdorf I,Porat S,Simantov R,et al.Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo[J].Br J Pharmacol,1999,126(4):997-1002.
  • 9Maruyama W,Yamamoto T,Kitani K,et al.Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine,rasagiline[J].Mech Ageing Dev,2000,116(2-3):181-191.
  • 10Mizuta I,Ohta M,Ohta K,et al.selegiline and desmethyl selegiline stimulate NGF,BDNF,and GDNF synthesis in cultured mouse astrocytes[J].Biochem Biophys Res Commun,2000,279(3):751-755.

共引文献19

同被引文献91

  • 1张晓录 ,张逢春 ,李尧华 .酪氨酸羟化酶与帕金森病的关系研究[J].北华大学学报（自然科学版）,2005,6(3):224-227. 被引量：12
  • 2王本祥,陈晓光.次黄嘌呤对单胺氧化酶的抑制作用[J].药学学报,1989,24(8):573-577. 被引量：40
  • 3黄海东,顾建文,赵凯,杨立斌,夏勋,张辉.偏侧PD猴模型黑质和纹状体GFAP表达的变化[J].中国神经免疫学和神经病学杂志,2007,14(3):130-132. 被引量：2
  • 4包新民 舒斯云.大鼠脑立体定位图谱[M].北京：人民卫生出版社,1981.35-55.
  • 5包新民 舒斯云.大鼠脑立体定位图谱[M].北京：人民卫生出版社,1990.25-28.
  • 6张海娜,胡国华,陈秋惠,孙冬,刘彩霞,孙亚娟.帕金森病细胞模型的建立及鱼藤酮对多巴胺能神经元的毒性作用[J].吉林大学学报（医学版）,2007,33(5):811-814. 被引量：9
  • 7All SF, Binienda ZK, Imam SZ, et al. Molecular aspects of dopaminergic neurodegeneration: gene -environment interaction in parkin dysfunction[J]. Int J Environ Res Public Health, 2011, 8(12): 4702-4713.
  • 8Phani S, Loike JD, Przedborski S. Neurodegeneration and inflammation in Parkinson's disease[J]. Parkinsonism Relat Disord, 2012, 18(suppl): S207-S209.
  • 9Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: its role in neuronal desth and implications for therapeutic intervention[J]. Neurobiol Dis, 2010, 37(3): 510-518.
  • 10Carvey PM, Chen EY, Lipton JW, et al. Intra-parenchymal injection of tumor necrosis factor-alpha and intedeukin 1- beta produees dopamine neuron loss in the rat[J]. J Neural Transm, 2005, 112: 601-612.

引证文献7

二级引证文献23

中国药物化学杂志
2011年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部